News | February 19, 2022
Jagsonpal Pharma inks agreement with Suvinys Developers
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
The brand has added a range of exciting new products especially formulated for oily skin.
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Subscribe To Our Newsletter & Stay Updated
